Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 5805-52-7 | MDL No. : | MFCD05723975 |
Formula : | C8H7N3O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | XIZCDQOKKYYCRH-UHFFFAOYSA-N |
M.W : | 161.16 | Pubchem ID : | 445686 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 44.19 |
TPSA : | 71.77 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.95 cm/s |
Log Po/w (iLOGP) : | 1.09 |
Log Po/w (XLOGP3) : | 0.47 |
Log Po/w (WLOGP) : | 0.66 |
Log Po/w (MLOGP) : | 0.18 |
Log Po/w (SILICOS-IT) : | 1.14 |
Consensus Log Po/w : | 0.71 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.62 |
Solubility : | 3.83 mg/ml ; 0.0238 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.55 |
Solubility : | 4.58 mg/ml ; 0.0284 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.49 |
Solubility : | 0.522 mg/ml ; 0.00324 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.31 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P273 | UN#: | N/A |
Hazard Statements: | H302-H412 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
55% | Stage #1: at 79℃; for 4 h; Stage #2: at 70℃; for 5 h; |
At room temperature,A solution of 3.0 g (18.6 mmol) of 1 H-benzimidone-2-carboxylic acid was addedPlaced in1OOmL before the bottle,Add 30mL of thionyl chloride, 79 ° C reflux reaction 4h,After the reaction, dry the solvent. Add 30mL of ammonia, 70 ° C reaction 5h, cooling the reaction solution,Filtration of yellow solid, dry. Yield: 55.0percent. |
55% | Stage #1: at 79℃; for 4 h; Stage #2: at 70℃; for 5 h; |
At room temperature,3.0 g (18.6 mmol) of 1H-benzimidazole-2-carboxylic acid was placed in a 100 mL eggplant type flask,Add 30mL of thionyl chloride, 79 reflux reaction 4h, after the end of the reaction evaporated solvent.Add 30mL ammonia water, 70 reaction 5h, cooling the reaction solution,Filtration of yellow solid, dry. The yield was 55percent. |
[ 43029-20-5 ]
3-Amino-6-methylpyrazin-2(1H)-one
Similarity: 0.65
[ 35252-02-9 ]
Pyrido[2,3-b]pyrazin-3(4H)-one
Similarity: 0.64
[ 5805-57-2 ]
(1H-Benzo[d]imidazol-2-yl)methanamine
Similarity: 0.84
[ 7757-21-3 ]
(1H-Benzo[d]imidazol-2-yl)methanamine hydrochloride
Similarity: 0.82
[ 5993-91-9 ]
(1H-Benzo[d]imidazol-2-yl)methanamine dihydrochloride
Similarity: 0.73
[ 29043-48-9 ]
2-Methyl-1H-benzoimidazol-5-ylamine
Similarity: 0.69
[ 5805-57-2 ]
(1H-Benzo[d]imidazol-2-yl)methanamine
Similarity: 0.84
[ 7757-21-3 ]
(1H-Benzo[d]imidazol-2-yl)methanamine hydrochloride
Similarity: 0.82
[ 3314-30-5 ]
1H-Benzo[d]imidazole-2-carbaldehyde
Similarity: 0.80
[ 3012-80-4 ]
1-Methyl-1H-benzo[d]imidazole-2-carbaldehyde
Similarity: 0.75
[ 5993-91-9 ]
(1H-Benzo[d]imidazol-2-yl)methanamine dihydrochloride
Similarity: 0.73